Lonza signs new long-term agreement with Alexion
Will construct a new manufacturing line at US facility in Portsmouth, NH
Lonza Group has signed a new long-term product supply agreement with Alexion under which the Swiss company will construct a new suite dedicated to manufacturing for the US pharmaceutical manufacturer.
Lonza will own and operate the suite as part of its Portsmouth, NH site in the US.
The large-scale manufacturing line will be operational by the end of 2017.
This contract is an expansion of an existing manufacturing agreement and expands production for Alexion products at multiple Lonza facilities.
The expansion of the Portsmouth facility will provide customers with increased access to Lonza’s proven biological manufacturing and regulatory expertise, experienced global workforce and high level of focused customer service.
Lonza COO Marc Funk said: 'I’m pleased to be reinforcing our long-standing strategic relationship with Alexion.
'Our new offering of suites with dedicated manufacturing capacity will give customers greater flexibility in determining production quantities and timings. At the same time, we’ll continue to offer our services in our multi-purpose plants to meet our customers’ needs.'
Julie O’Neill, Executive Vice President, Global Operations at Alexion, added: 'Developing a robust supply chain for our pipeline and commercial products is essential as we aim to serve more patients with our growing portfolio of life-transforming therapies.'
